Optimizing quantification of MK6240 tau PET in unimpaired older adults.

ABSTRACT: Accurate measurement of Alzheimer's disease (AD) pathology in older adults without significant clinical impairment is critical to assessing intervention strategies aimed at slowing AD-related cognitive decline. The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (POINTER) is a 2-year randomized controlled trial to evaluate the effect of multicomponent risk reduction strategies in older adults (60-79 years) who are cognitively unimpaired but at increased risk for cognitive decline/dementia due to factors such as cardiovascular disease and family history. The POINTER Imaging ancillary study is collecting tau-PET ([¹⁸F]MK6240), beta-amyloid (Aβ)-PET ([¹⁸F]florbetaben [FBB]) and MRI data to evaluate neuroimaging biomarkers of AD and cerebr

SUBMITTER: Harrison TM 

PROVIDER: S-EPMC9957642 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature